# Safety and Efficacy of Pucotenlimab in pLECC

> **NCT06969534** · PHASE2 · RECRUITING · sponsor: **Sun Yat-sen University** · enrollment: 33 (estimated)

## Conditions studied

- Lymphoepithelioma-like Carcinoma
- Lymphoepithelioma
- Carcinoma

## Interventions

- **DRUG:** Pucotenlimab combined with GP regimen

## Key facts

- **NCT ID:** NCT06969534
- **Lead sponsor:** Sun Yat-sen University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-05-15
- **Primary completion:** 2027-12-30
- **Final completion:** 2028-12-30
- **Target enrollment:** 33 (ESTIMATED)
- **Last updated:** 2025-05-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06969534

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06969534, "Safety and Efficacy of Pucotenlimab in pLECC". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT06969534. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*